Issue 5, 2015

Synthetic artificial microRNAs targeting UCA1-MALAT1 or c-Myc inhibit malignant phenotypes of bladder cancer cells T24 and 5637

Abstract

The biggest concern of using natural microRNAs for treating cancer is that they usually cause few phenotypic changes due to the divergent functions of their target genes. Based on the engineering principles of synthetic biology, we provided a standard platform for constructing artificial microRNAs that can target one or few specific genes and silence both protein-coding genes and long non-coding genes. To prove the utility of this platform, we chose MALAT1, UCA1, and c-Myc as the functional targets and used the bladder cancer cell lines T24 and 5637 as the test models. The relative expression level of the target genes was measured by qRT-PCR. Cell proliferation and migration were determined by MTT assay and wound-healing assay, respectively. Cell apoptosis was revealed by both Hoechst 33258 staining assay and ELISA assay. We found that the artificial microRNAs can effectively silence their target genes and induce anti-cancer effects in T24 and 5637 cells. These devices can inhibit proliferation, induce apoptosis, and suppress migration of the two bladder cancer cell lines. The synthetic artificial microRNAs may represent a kind of novel genetic devices for treating human bladder cancer.

Graphical abstract: Synthetic artificial microRNAs targeting UCA1-MALAT1 or c-Myc inhibit malignant phenotypes of bladder cancer cells T24 and 5637

Article information

Article type
Paper
Submitted
10 Feb 2015
Accepted
09 Mar 2015
First published
11 Mar 2015

Mol. BioSyst., 2015,11, 1285-1289

Synthetic artificial microRNAs targeting UCA1-MALAT1 or c-Myc inhibit malignant phenotypes of bladder cancer cells T24 and 5637

X. Fu, Y. Liu, C. Zhuang, L. Liu, Z. Cai and W. Huang, Mol. BioSyst., 2015, 11, 1285 DOI: 10.1039/C5MB00127G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements